A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

144 Appendix 3 TABLE 69 Studies excluded from clinical effectiveness review (cont’d) Citation Reason for exclusion/comment Ferraro-Peyret et al., 2004223 Non-randomised study investigating infliximab treatment and autoantibodies in RA and ankylosing spondylitis patients Genovese et al., 2001 224 Three-year outcomes from the extension of etanercept ERA trial in which patient no longer remained on randomised treatment. Abstract Genovese et al., 2002 225 Four-year outcomes from the extension of etanercept ERA trial in which patient no longer remained on randomised treatment. Abstract Genovese et al., 2003 226 Five-year outcomes from the extension of etanercept ERA trial in which patient no longer remained on randomised treatment. Abstract Gomez-Puerta et al., 2004 227 Observational study of using etanercept after treatment failure with infliximab with no control group Korczowska et al., 2003 228 Non-randomised study investigating infliximab treatment and bone turnover Kucharz et al., 2003 229 Non-randomised study investigating infliximab treatment and serum endostatin level Osborn, 2002 230 Abstract. Double-blind controlled study of single injection of intra-articular etanercept versus saline in RA patients. No mention of randomisation Saadeh et al., 2002 231 Non-randomised study investigating infliximab treatment and asthma control in RA patients. Abstract Smith et al., 2004 232 Case report of treating renal amyloidosis complicating RA with etanercept Yazici et al., 2001 233 Review articles Non-randomised study comparing the efficacy of etanercept with infliximab. Abstract Breedveld, 2001 234 Review of TNF blockade in RA Calin, 2003 235 Review of infliximab Muhlhauser, 2003 236 Review of etanercept (German) Pugsley, 2001 237 Review of etanercept Rashmi and Ujala, 2004 238 Review of novel therapeutic approach for RA Rau, 2002 239 Review of adalimumab treatment in RA Sautner, 2005 240 Review of adalimumab (German) Vervaeren, 2002 241 Review of new treatment in RA (French) Winning, 2001 242 Review of infliximab treatment in RA Yung, 2001 243 Review of etanercept News articles/commentaries/editorials Anonymous, 2003 244 Summary of adalimumab DE019 (German) Anonymous, 2004 245 News on Genovese et al., 2004 157 listed above, which compared the combination of anakinra and etanercept and etanercept alone Bain and Brazil, 2003 246 Commentary on adalimumab Becker, 2004 247 News article on adalimumab (German) Boers, 2001248 Letter. Commentary on ATTRACT Bruhn, 2002249 Commentary on adalimumab (German) Bruhn, 2004250 News article on TEMPO (German) Choy, 2004251 Editorial on combination therapy Cutolo, 2001252 Commentary on an etanercept RCT Czajka, 2001253 News article on ATTRACT (German) Haneveld, 2004254 News article on TEMPO (Dutch) Hellwig, 2003255 Commentary on adalimumab (German) Masche, 2003256 Commentary on adalimumab (German) Matucci-Cerinic, 2004257 Commentary on ARMADA Moreland, 2004258 Commentary on an infliximab RCT Moreland, 2004259 Commentary on an adalimumab RCT Rothschild, 2002260 Conference news report regarding TNF therapies continued
TABLE 69 Studies excluded from clinical effectiveness review (cont’d) Citation Reason for exclusion/comment Irrelevant (conference news reports; cost studies) Braddock, 2004 261 Conference news report Croasdell, 2003 262 Conference news report Evans, 2003 263 Conference news report Levy et al., 2004 264 Conference news report Oelke, 2002 265 Conference news report Trepman et al., 2003 266 Conference news report Yung, 2002 267 Conference news report van de Putte et al., 2002 268 Cost study for an adalimumab trial. Abstract EULAR, European League Against Rheumatism. © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 145
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110: TABLE 39 Strategy set: adalimumab a
Page 111 and 112: TABLE 43 Beta distributions for HAQ
Page 113 and 114: TABLE 44 Early cessation of DMARDs:
Page 115 and 116: TABLE 46 Unit costs for tests and v
Page 117 and 118: following properties, according to
Page 119 and 120: TABLE 52 Base case: TNF inhibitors
Page 121 and 122: TABLE 54 Base case: TNF inhibitors
Page 123 and 124: TABLE 59 Third TNF inhibitor follow
Page 125 and 126: TABLE 65 Sensitivity analyses: TNF
Page 127 and 128: TABLE 67 Sensitivity analyses: TNF
Page 129: The substantial economic impact of
Page 133 and 134: Summary Effectiveness: principal fi
Page 135 and 136: inhibitors, although the incrementa
Page 137 and 138: introduce bias which generally exag
Page 139: Adalimumab, etanercept and inflixim
Page 143 and 144: 1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146: 46. Young A, Dixey J, Cox N, Davies
Page 147 and 148: tumor necrosis factor therapy in th
Page 149 and 150: arthritis: a 12-week, double-blind,
Page 151 and 152: 171. Geborek P, Crnkic M, Petersson
Page 153 and 154: 216. Schotte H, Willeke P, Mickholz
Page 155 and 156: The Health Assessment Questionnaire
Page 157 and 158: Cochrane Library (CENTRAL) 2005 Iss
Page 159: Appendix 3 © Queen’s Printer and
Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169: 152 Appendix 4 Infliximab versus pl
Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
Page 173: Ovid MEDLINE(R) 1966 to February we
Page 177 and 178: Appendix 8 © Queen’s Printer and
Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
Page 187 and 188: TABLE 85 Bansback et al., 2005 166
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 211 and 212:
TABLE 117 Variation 6: TNF inhibito
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
TABLE 132 Variation 10: TNF inhibit
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243:
Page 247 and 248:
Volume 1, 1997 No. 1 Home parentera
Page 249 and 250:
No. 3 Screening for sickle cell dis
Page 251 and 252:
No. 25 A rapid and systematic revie
Page 253 and 254:
No. 11 First and second trimester a
Page 255 and 256:
No. 23 Clinical effectiveness and c
Page 257 and 258:
No. 28 Outcomes of electrically sti
Page 259:
No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263:
246 Health Technology Assessment Pr
Page 264:
248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?